Nanomaterials for drug delivery and theranostics: Junction Brief – November 2026

Acentric Research is produced with AI tools under human review. The authors are not financial professionals, and nothing here is investment advice or a recommendation to buy or sell any security. AI analysis can be wrong; check every claim against its cited source.

This Brief is an initial scan, not a full investigation. The method and scores behind it are in Biotechnology × Materials in the Landscape Report.

Overview

Many drugs work only if they reach the right cells in the right amount. Nanomaterials, particles far smaller than a cell, can protect a drug on the way and help release it at the target. Some also combine imaging with treatment, a pairing called theranostics. The material decides what the particle carries, where it goes and how it breaks down, so this is a materials problem as much as a drug problem.

The sources opened show one product with an FDA drug label that uses a lipid-based delivery system, and one targeted version in an early human study. This Brief names examples only. A lipid-based delivery system is part of an FDA-approved drug for a rare hereditary disease. [1] One company has registered a Phase 1 study of a targeted lipid-particle product. [2] This area overlaps with pharmaceuticals, so it is hard to separate the particle from the drug it carries. The dated sources opened run from 2022 to 2025; later developments were not searched.

Current state

Public research funding. NIBIB's Nanomaterials program "supports the development and demonstration of broadly applicable nanomaterials to enable new paradigms of human health." Its funded-projects page, read on the access date, lists three projects: a protein-based self-assembling nanoplatform for a type of breast cancer, a method of loading drugs into nanovesicles, and nucleic-acid nanoparticles that mimic antibodies. [3][4]

What is approved. FDA's label for ONPATTRO, a drug indicated for the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, says the drug is a small interfering RNA "formulated as a lipid complex for delivery to hepatocytes", the main cells of the liver. [1] The label names Alnylam Pharmaceuticals as the manufacturer and was last effective on 8 September 2025. [1] A research review describes polymer-based, lipid-based and conjugate-based systems for carrying RNA drugs, which it says circumvent the limitations of viral delivery vectors, and the path from preclinical research to approval. [5]

Companies in their own words. Capstan Therapeutics describes its work as in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles. Its lead candidate, CPTX2309, delivers messenger RNA that encodes an anti-CD19 chimeric antigen receptor to a type of immune cell, with the stated aim of resetting the immune system in autoimmune disease (company announcement as reported by Pulse 2.0, March 2024). [6] ClinicalTrials.gov lists a Phase 1 study of CPTX2309 given intravenously to healthy participants and to people with rheumatoid arthritis or lupus, started 9 April 2025 and recruiting as read on the access date. [2] Serina Therapeutics describes its POZ technology as based on a synthetic, water-soluble polymer called poly(2-oxazoline), for drugs given by subcutaneous injection, and says its candidates are typically well-understood, marketed drugs limited by their pharmacokinetic profiles. In a filing, it reported that 2023 revenue of $3.2 million came largely from a one-time upfront payment of $3.0 million under a non-exclusive license with Pfizer to use the polymer in lipid-nanoparticle formulations (company filing). [7]

How far it has come. Lipid delivery is in an approved medicine. [1] Targeted lipid particles are in a Phase 1 study that started in 2025. [2] The sources opened do not show an approved theranostic product.

Opportunities

If targeting works, a particle could carry instructions to specific cells inside the body. Capstan states that its lead program delivers messenger RNA to T cells in the body to engineer them there, with the aim of resetting the immune system in autoimmune disease. [6] Serina's filing records a license agreement with Pfizer for use of its polymer in particle formulations; a license is a business event, not a result. The company also says its platform has potential for use across a broad range of payloads and indications and that it intends to pursue out-licensing, co-development or other partnerships (company statements). [7] The evidence that would show progress is human data on safety and on whether the particles reach the intended cells.

Challenges

  • Biology and engineering. The Nature Reviews Genetics abstract frames the work as design for getting RNA into target cells without unwanted immune responses, and distinguishes systems that target passively from those that target actively. [5]
  • Regulation. The study of CPTX2309 is Phase 1; the sources opened give no efficacy result. [2] Each new particle and payload goes through its own drug review.
  • Capital and scale-up. Capstan reported a $175 million Series B in March 2024 (company announcement reported by trade press); such amounts are disclosed by companies and are not a measure of technical progress. [6] Serina's filing reports that its 2024 revenue was entirely NIH grant revenue; later results were not checked. [7]

Data sources

  • ClinicalTrials.gov and Drugs@FDA or openFDA labels, for studies and approved products that use these materials. [8][9]
  • NIH RePORTER and NIBIB program pages, for grants. [10][4]
  • SEC EDGAR, for licenses and revenue disclosed by public companies. [11]
  • Europe PMC, for the research literature. [12]
  • Because particles and drugs are reported together, no source counts delivery materials on their own.

Changelog

  • 2026-11-18: First published.

Sources

  1. U.S. Food and Drug Administration drug label for ONPATTRO (patisiran), label effective 2025-09-08, application NDA210922, read through the openFDA label API. api.fda.gov (accessed 2026-11-18)
  2. ClinicalTrials.gov, NCT06917742, "A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)" (registry record; sponsor query "Capstan Therapeutics", API v2). clinicaltrials.gov (accessed 2026-11-18)
  3. NIBIB, "Nanomaterials", program page (agency statement). nibib.nih.gov (accessed 2026-11-18)
  4. National Institute of Biomedical Imaging and Bioengineering (NIBIB), "Funded Projects for Nanomaterials" and the Nanomaterials program page (agency statements; the funded-projects page lists three projects as read). nibib.nih.gov (accessed 2026-11-18)
  5. Kalina Paunovska, David Loughrey and James E. Dahlman, "Drug delivery systems for RNA therapeutics", Nature Reviews Genetics, 2022, abstract (Europe PMC record, PMID 34983972; the full text was not read). ebi.ac.uk(accessed 2026-11-18)
  6. Pulse 2.0, "Capstan Therapeutics: $175 Million Raised To Advance Reprogramming Of Cells Through RNA Delivery", 2024-03-21 (trade press reporting a company announcement). pulse2.com (accessed 2026-11-18)
  7. Serina Therapeutics, Form 8-K exhibit 99.1 (earnings release), filed 2025-03-24 (company filing). sec.gov(accessed 2026-11-18)
  8. ClinicalTrials.gov, study search. clinicaltrials.gov (listed as a data source; opened through its API only for two sponsor queries, 2026-11-18; not searched for this Junction)
  9. openFDA, drug label and Drugs@FDA data. open.fda.gov (the label API was queried for one product, 2026-11-18)
  10. NIH RePORTER, project search. reporter.nih.gov (listed as a data source, not opened for this Brief)
  11. SEC EDGAR, full-text search. sec.gov (listed as a data source; one exhibit was opened by its archive address, and the search itself was not run for this Brief)
  12. Europe PMC REST API. ebi.ac.uk (listed as a data source; two review abstracts were read through its API for other claims, 2026-11-18; not searched for this Junction)